Will GoodRX Stock Bounce Back?
GoodRX (NASDAQ:GDRX) tracks prescription drug prices and its model was…
Sell
2
RARE Quote, Financials, Valuation and Earnings
Last price:
$27.41
Seasonality move
:
-4.41%
Day range:
$27.11 - $28.02
52-week range:
$26.85 - $60.37
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
4.32x
P/B ratio:
17.90x
Volume:
3M
Avg. volume:
2M
1-year change:
-39.67%
Market cap:
$2.6B
Revenue:
$560.2M
EPS (TTM):
-$5.88
Earnings Data
Next earnings date for RARE
Aug 01
2025
Most recent earnings per share
-$1.57
Beat by $0.07
(May 6/2025)
Consensus Estimate
-$1.64
(May 6/2025)
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
RARE Quarterly Earnings History
| Date | Quarter | Revenue Forecast | Actual Revenue | Reported EPS | Consensus EPS | Beat/Miss |
|---|---|---|---|---|---|---|
| 09/30/2025 | Q3 | $164.2M | -- | -- | -$1.31 | -- |
| 08/01/2025 | Q2 | $161.1M | -- | -- | -$1.33 | -- |
| 05/06/2025 | Q1 | $144.5M | $139.3M | -$1.57 | -$1.64 | $0.07 |
| 02/13/2025 | Q4 | $158.7M | $164.9M | -$1.39 | -$1.27 | -$0.12 |
| 11/05/2024 | Q3 | $135.2M | $139.5M | -$1.40 | -$1.47 | $0.07 |
| 08/01/2024 | Q2 | $123.2M | $147M | -$1.52 | -$1.63 | $0.11 |
| 05/02/2024 | Q1 | $116.4M | $108.8M | -$2.03 | -$1.72 | -$0.31 |
| 02/15/2024 | Q4 | $121M | $127.4M | -$1.52 | -$1.61 | $0.09 |
| 11/02/2023 | Q3 | -- | -- | -$2.23 | -$2.01 | -$0.22 |
| 08/03/2023 | Q2 | -- | -- | -$2.25 | -$2.02 | -$0.23 |
| 05/04/2023 | Q1 | -- | -- | -$2.33 | -$1.61 | -$0.72 |
| 02/16/2023 | Q4 | -- | -- | -$2.16 | -$1.80 | -$0.36 |
| 11/02/2022 | Q3 | -- | -- | -$3.50 | -$2.40 | -$1.10 |
| 07/28/2022 | Q2 | -- | -- | -$2.26 | -$1.64 | -$0.62 |
| 05/05/2022 | Q1 | -- | -- | -$2.19 | -$1.78 | -$0.41 |
| 02/10/2022 | Q4 | -- | -- | -$1.79 | -$1.19 | -$0.60 |
| 11/02/2021 | Q3 | -- | -- | -$1.08 | -$1.10 | $0.02 |
| 08/02/2021 | Q2 | -- | -- | -$1.81 | -$1.05 | -$0.76 |
| 05/04/2021 | Q1 | -- | -- | -$2.03 | -$1.29 | -$0.74 |
| 02/11/2021 | Q4 | -- | -- | -$0.37 | -$1.14 | $0.77 |
| 10/27/2020 | Q3 | -- | -- | -$1.13 | -$1.07 | -$0.07 |
| 07/30/2020 | Q2 | -- | -- | $0.41 | -$1.73 | $2.14 |
| 05/06/2020 | Q1 | -- | -- | -$2.05 | -$1.68 | -$0.37 |
| 02/13/2020 | Q4 | -- | -- | -$1.62 | -$1.53 | -$0.09 |
| 11/05/2019 | Q3 | -- | -- | -$1.96 | -$1.55 | -$0.41 |
| 08/01/2019 | Q2 | -- | -- | -$1.90 | -$1.59 | -$0.30 |
| 05/06/2019 | Q1 | -- | -- | -$1.82 | -$1.67 | -$0.15 |
| 02/19/2019 | Q4 | -- | -- | -$1.73 | -$1.87 | $0.14 |
| 11/05/2018 | Q3 | -- | -- | -$1.74 | -$1.99 | $0.25 |
| 08/02/2018 | Q2 | -- | -- | -$1.87 | -$2.13 | $0.26 |
| 05/07/2018 | Q1 | -- | -- | -$2.07 | -$0.87 | -$1.20 |
| 02/20/2018 | Q4 | -- | -- | -$2.27 | -$1.99 | -$0.28 |
| 11/02/2017 | Q3 | -- | -- | -$1.87 | -$1.87 | $0.00 |
| 07/27/2017 | Q2 | -- | -- | -$1.72 | -$1.71 | -$0.01 |
| 05/08/2017 | Q1 | -- | -- | -$1.63 | -$1.71 | $0.08 |
| 02/16/2017 | Q4 | -- | -- | -- | -- | -- |
| 11/07/2016 | Q3 | -- | -- | -- | -- | -- |
| 08/09/2016 | Q2 | -- | -- | -- | -- | -- |
| 05/09/2016 | Q1 | -- | -- | -- | -- | -- |
| 02/25/2016 | Q4 | -- | -- | -- | -- | -- |
| 11/09/2015 | Q3 | -- | -- | -- | -- | -- |
Ultragenyx Pharmaceutical Earnings Questions
-
How Much did Ultragenyx Pharmaceutical Generate in Revenue Last Quarter?
Ultragenyx Pharmaceutical reported $139.3M worth of top line sales in its most recent quarter.
-
Did Ultragenyx Pharmaceutical Beat Earnings Last Quarter?
Ultragenyx Pharmaceutical announced earnings per share of -$1.57 which represents a beat of analyst forecast a -$1.64 per share.
-
Is Ultragenyx Pharmaceutical Profitable?
Ultragenyx Pharmaceutical reported $110.6M that represents $1.15 per share over the last quarter.
-
What is the Analyst Consensus for Ultragenyx Pharmaceutical EPS Next Year?
Ultragenyx Pharmaceutical's earnings are forecast to decrease from -$6.29 per share to -$6.17 per share next year representing a decrease of -15.6%.
-
When is Ultragenyx Pharmaceutical's Earnings Date?
Ultragenyx Pharmaceutical's next earnings date is August 1, 2025.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will FCX Benefit From Tariffs?
Freeport-McMoRan (NYSE:FCX) is among the world’s largest producers of copper…
Can Levi Stock Double?
Levi Strauss (NYSE:LEVI) is among the oldest clothing brands in…
Stock Ideas
Buy
70
Is NVDA Stock a Buy?
Market Cap: $4.2T
P/E Ratio: 58x
Buy
62
Is MSFT Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 43x
Sell
40
Is AAPL Stock a Buy?
Market Cap: $3.1T
P/E Ratio: 35x
Alerts
Buy
82
SBET alert for Jul 17
SharpLink Gaming [SBET] is down 2.6% over the past day.
Buy
89
EXOD alert for Jul 17
Exodus Movement [EXOD] is down 4.14% over the past day.
Buy
60
U alert for Jul 17
Unity Software [U] is up 7.51% over the past day.
